1,139 results on '"Delforge, Michel"'
Search Results
152. Use of interval-specific likelihood ratios improves clinical interpretation of serum FLC results for the diagnosis of malignant plasma cell disorders
153. Additional file 1 of Quality of life analyses in patients with multiple myeloma: results from the Selinexor (KPT-330) Treatment of Refractory Myeloma (STORM) phase 2b study
154. Additional file 2 of Quality of life analyses in patients with multiple myeloma: results from the Selinexor (KPT-330) Treatment of Refractory Myeloma (STORM) phase 2b study
155. Quality of life analyses in patients with multiple myeloma: results from the Selinexor (KPT-330) Treatment of Refractory Myeloma (STORM) phase 2b study
156. Multiple myeloma: EHA-ESMO clinical practice guidelines for diagnosis, treatment and follow-up
157. COVID-19 vaccination in patients with multiple myeloma: a consensus of the European Myeloma Network
158. Bone healing with bortezomib-based regimens in multiple myeloma: a retrospective imaging study
159. CARTITUDE-2: Efficacy and safety of ciltacabtagene autoleucel (cilta-cel), a BCMA-directed CAR T-cell therapy, in patients with progressive multiple myeloma (MM) after one to three prior lines of therapy.
160. Matching adjusted indirect comparisons of efficacy outcomes for idecabtagene vicleucel (ide-cel, bb2121) versus selinexor + dexamethasone and belantamab mafodotin in relapsed and refractory multiple myeloma
161. P-294 Comparative effectiveness of teclistamab vs real-world physician's choice of therapy in the LocoMMotion and MoMMent studies for patients with triple-class exposed relapsed/refractory multiple myeloma
162. Iron status and treatment modalities in transfusion-dependent patients with myelodysplastic syndromes
163. Aprotinin Reduces Cardiac Troponin I Release and Inhibits Apoptosis of Polymorphonuclear Cells During Off-Pump Coronary Artery Bypass Surgery
164. The clinical significance of activated lymphocytes in patients with myelodysplastic syndromes: A single centre study of 131 patients
165. Lenalidomide and Dexamethasone in Transplant-Ineligible Patients with Myeloma
166. Being a hematologist
167. Response evaluation and monitoring of multiple myeloma
168. Recommendations on the management of multiple myeloma in 2020.
169. Immunomodulators in newly diagnosed multiple myeloma: current and future concepts
170. Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma
171. Immature and mature monocyte-derived dendritic cells in myelodysplastic syndromes of subtypes refractory anemia or refractory anemia with ringed sideroblasts display an altered cytokine profile
172. Erratum to: Practical Considerations for the Use of Daratumumab, a Novel CD38 Monoclonal Antibody, in Myeloma
173. Recommendations on the management of multiple myeloma in 2020
174. Secondary Quality-of-Life Domains in Patients with Relapsed and Refractory Multiple Myeloma Treated with the Bcma-Directed CAR T Cell Therapy Idecabtagene Vicleucel (ide-cel; bb2121): Results from the Karmma Clinical Trial
175. Health State Utility Valuation in Patients with Triple-Class-Exposed Relapsed and Refractory Multiple Myeloma Treated with the Bcma-Directed CAR T Cell Therapy, Idecabtagene Vicleucel (ide-cel, bb2121): Results from the Karmma Trial
176. KarMMa-3: A Phase 3 Study of Idecabtagene Vicleucel (ide-cel, bb2121), a BCMA-Directed CAR T Cell Therapy Vs Standard Regimens in Relapsed and Refractory Multiple Myeloma
177. Efficacy and safety profile of deep responders to carfilzomib-based therapy: a subgroup analysis from ASPIRE and ENDEAVOR
178. Multiple myeloma treatment in the elderly
179. Health-related quality of life in elderly, newly diagnosed multiple myeloma patients treated with VMP vs. MP: results from the VISTA trial
180. Continuous Lenalidomide Treatment for Newly Diagnosed Multiple Myeloma
181. Fewer bone disease events, improvement in bone remodeling, and evidence of bone healing with bortezomib plus melphalan-prednisone vs. melphalan-prednisone in the phase III VISTA trial in multiple myeloma
182. A double-edged sword
183. Recommendations for vaccination in multiple myeloma: a consensus of the European Myeloma Network
184. Upfront stem cell transplantation for newly diagnosed multiple myeloma with del(17p) and t(4;14): a study from the CMWP-EBMT
185. Recent Advancements in Hematology: Knowledge, Methods and Dissemination, Part 1
186. Novel risk stratification algorithm for estimating the risk of death in patients with relapsed multiple myeloma: external validation in a retrospective chart review
187. COVID-19, impact on myeloma patients
188. Ultra‐low depth sequencing of plasma cell DNA for the detection of copy number aberrations in multiple myeloma
189. Comparison of 2 Serum-Free Light-Chain Assays in CKD Patients
190. Different MAF translocations confer similar prognosis in newly diagnosed multiple myeloma patients
191. A multicenter retrospective study of 223 patients with t(14;16) in multiple myeloma
192. Pharmacokinetics of chemotherapeutic agents in pregnancy: a preclinical and clinical study
193. Velocities of Naturally Occurring Myocardial Shear Waves Increase With Age and in Cardiac Amyloidosis
194. Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study
195. Characterization of Relapse and Second-Line Therapy in Lenalidomide-Refractory, Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma: A Subanalysis of the Phase 3 First Trial
196. The Locommotion Study (MMY4001): A Prospective, Multinational Study of Real-Life Current Standards of Care in Patients with Relapsed and/or Refractory Multiple Myeloma Who Received at Least 3 Prior Lines of Therapy Including PI, IMiD, and CD38 Monoclonal Antibody Treatment and Documented Disease Progression
197. Health-Related Quality of Life in Patients with Relapsed/Refractory Multiple Myeloma Treated with Isatuximab Plus Pomalidomide and Dexamethasone: Icaria-MM Study
198. Daratumumab, Lenalidomide, and Dexamethasone (D-Rd) Delivers a Reduction and Delay in Worsening of Pain Symptoms for Patients with Newly Diagnosed Multiple Myeloma Ineligible for Transplant
199. Daratumumab Plus Bortezomib, Thalidomide, and Dexamethasone (D-VTd) in Transplant-eligible Newly Diagnosed Multiple Myeloma (NDMM): Subgroup Analysis of High-risk Patients (Pts) in CASSIOPEIA
200. Concordance of Post-consolidation Minimal Residual Disease Rates by Multiparametric Flow Cytometry and Next-generation Sequencing in CASSIOPEIA
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.